Compare Natco Pharma with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA PANACEA BIOTECH NATCO PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 31.6 8.8 358.8% View Chart
P/BV x 4.5 3.4 131.0% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 NATCO PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    NATCO PHARMA
Mar-19
PANACEA BIOTECH
Mar-19
NATCO PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs849354 240.1%   
Low Rs557138 403.0%   
Sales per share (Unadj.) Rs573.874.6 769.6%  
Earnings per share (Unadj.) Rs176.06.7 2,635.1%  
Cash flow per share (Unadj.) Rs198.215.5 1,279.0%  
Dividends per share (Unadj.) Rs6.250-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs842.757.2 1,473.1%  
Shares outstanding (eoy) m36.5061.25 59.6%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x1.23.3 37.1%   
Avg P/E ratio x4.036.8 10.8%  
P/CF ratio (eoy) x3.515.9 22.4%  
Price / Book Value ratio x0.84.3 19.4%  
Dividend payout %3.60-   
Avg Mkt Cap Rs m25,66015,061 170.4%   
No. of employees `0005.02.3 214.2%   
Total wages/salary Rs m3,5591,471 242.0%   
Avg. sales/employee Rs Th4,225.31,973.6 214.1%   
Avg. wages/employee Rs Th718.0635.6 113.0%   
Avg. net profit/employee Rs Th1,295.9176.8 733.0%   
INCOME DATA
Net Sales Rs m20,9454,567 458.6%  
Other income Rs m1,30245 2,906.3%   
Total revenues Rs m22,2474,612 482.4%   
Gross profit Rs m7,9482,030 391.6%  
Depreciation Rs m810540 150.0%   
Interest Rs m1931,048 18.4%   
Profit before tax Rs m8,247486 1,696.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,82377 2,364.5%   
Profit after tax Rs m6,424409 1,570.3%  
Gross profit margin %37.944.4 85.4%  
Effective tax rate %22.115.9 139.4%   
Net profit margin %30.79.0 342.4%  
BALANCE SHEET DATA
Current assets Rs m23,4722,415 972.1%   
Current liabilities Rs m7,2879,077 80.3%   
Net working cap to sales %77.3-145.9 -53.0%  
Current ratio x3.20.3 1,211.0%  
Inventory Days Days9265 141.7%  
Debtors Days Days8871 124.4%  
Net fixed assets Rs m18,6488,333 223.8%   
Share capital Rs m36561 595.4%   
"Free" reserves Rs m34,5253,443 1,002.8%   
Net worth Rs m30,7603,504 877.9%   
Long term debt Rs m0461 0.0%   
Total assets Rs m43,03113,755 312.8%  
Interest coverage x43.71.5 2,987.5%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.50.3 146.6%   
Return on assets %15.410.6 145.1%  
Return on equity %20.911.7 178.9%  
Return on capital %27.438.7 70.9%  
Exports to sales %020.9 0.0%   
Imports to sales %08.1 0.0%   
Exports (fob) Rs mNA954 0.0%   
Imports (cif) Rs mNA372 0.0%   
Fx inflow Rs m11,5361,203 958.9%   
Fx outflow Rs m2,939467 629.8%   
Net fx Rs m8,597736 1,167.5%   
CASH FLOW
From Operations Rs m6,6881,049 637.7%  
From Investments Rs m-6,122-54 11,443.0%  
From Financial Activity Rs m-509-1,011 50.3%  
Net Cashflow Rs m66-20 -335.0%  

Share Holding

Indian Promoters % 52.0 74.5 69.9%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 0.6 1,306.7%  
FIIs % 16.6 1.3 1,279.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 23.6 110.2%  
Shareholders   25,395 10,259 247.5%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   IPCA LABS  SANOFI INDIA  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  NOVARTIS  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views on News

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Mar 5, 2021 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - GSK PHARMA COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS